If you’ve been tracking the markets this week, you may have noticed something unusual: two big names — Corona Remedies and Wakefit Innovations — both opened their IPOs with strong brand recall, but investor sentiment has been surprisingly cautious.
The Corona Remedies IPO, despite being backed by a well-known pharmaceutical player, is showing signs of fatigue in the grey market. Meanwhile, the Wakefit IPO, from the beloved D2C home solutions brand, has started slow on Day 1 with muted subscription.
But why?
Why are investors beginning to hit the brakes on issues that would have created far more buzz just 12 months ago?
This article breaks down exactly what’s happening, what the DRHP reveals, what risks investors need to keep an eye on, and how both IPOs fit into the changing mood of the Indian markets.
Let’s dive in.
📌 Corona Remedies IPO: Why GMP Is Cooling Despite Steady Subscription
IPO grey market premiums behave like the monsoon — unpredictable, emotional, and often driven by small shifts in sentiment. For Corona Remedies, the GMP has slipped to just above 20%, far below earlier highs.
On paper, the IPO looks strong. But once you dig into the DRHP risk factors, you start to understand why investors are becoming more cautious.
Below, we break down the most important risks highlighted in the IPO documents — rewritten in simple, human language so you truly understand the story behind the numbers.
1️⃣ Heavy Dependence on Key Therapeutic Segments
If pharma were like cricket, then Corona Remedies plays with just two star batsmen.
Over ₹972 crore of revenue in Q2FY26 came from just two therapeutic categories.
That means:
- If patient demand shifts
- If a competitor launches a cheaper version
- Or if regulations tighten in those areas
…the company’s entire batting lineup can collapse.
In business terms: over-concentration is dangerous, especially in pharma where product cycles—and doctor prescriptions—can change fast.
What You Should Remember
A company dependent on a few therapeutic areas is like a shop that sells only two popular products — great when things are normal, risky when trends change.
2️⃣ Revenue Hinges on “Engine Brands” — The Core Money-Makers
Almost every pharma company has 4–5 “engine brands” — products that bring in consistent prescription volumes and repeat business.
For Corona Remedies, these brands are the heart of domestic sales.
But the challenge?
If one major brand gets hit — due to new competitors, supply issues, adverse clinical data, or pricing pressure — it can disproportionately affect revenue.
What You Should Remember
When most of your revenue comes from a few brands, the entire business behaves like a chair with two legs — stable until one leg cracks.
3️⃣ Over 85% of Revenue Comes From India
Corona Remedies is a domestic-heavy player, and while this is great for market familiarity, it is not without risk.
If India’s pharmaceutical market:
- Slows down
- Faces price caps
- Experiences regulatory tightening
…the company may face serious pressure.
A business with limited global diversification simply does not have backup engines when the primary engine slows.
What You Should Remember
A local-heavy revenue model is profitable during strong cycles, but it leaves the company exposed during shocks or regulatory tightening.
4️⃣ Revenue Concentrated in Five States
A surprising amount of revenue comes from:
- Gujarat
- Maharashtra
- Chhattisgarh
- Goa
- Madhya Pradesh
This creates geographic concentration risk.
If any of these states face:
- Healthcare supply disruption
- Regulatory change
- Regional slowdown
it can directly affect Corona Remedies’ sales pipeline.
What You Should Remember
Diversification is insurance. When your business depends heavily on a few regions, even small local issues can create national financial impact.
5️⃣ Dominance in Chronic & Sub-Chronic Segments
Over 70% of domestic revenue as of June 2025 came from chronic and sub-chronic therapies.
These are long-term treatment areas—like diabetes, hypertension, and thyroid issues—but they come with their own challenges:
- They’re deeply regulated
- They often face price caps
- They involve long treatment cycles
- Competition is fierce
- Government pricing intervention can disrupt margins overnight
What You Should Remember
Chronic therapies offer steady demand but unpredictable margins. One regulatory update can squeeze revenue dramatically.
6️⃣ Dependence on Third-Party Suppliers Without Long-Term Contracts
The company does not have long-term agreements for raw materials or finished goods.
This creates three major risks:
- Supply disruptions (strikes, shortages, logistics issues)
- Sudden cost hikes in APIs or packaging
- Quality control risks when relying on outside vendors
In pharma, even a minor supply issue can shut down production for weeks — and that means lost market share.
What You Should Remember
A business that relies heavily on third parties without contracts is always exposed to unpredictable costs and supply chain uncertainty.
7️⃣ Pending Regulatory & Tax Actions
Currently:
- Six regulatory actions are pending
- ₹1.69 crore worth of tax proceedings exist against the promoter group
While the amounts may not be massive, regulatory uncertainty casts a long shadow over pharma IPOs.
What You Should Remember
In pharma, regulatory clarity is as important as product quality. Pending actions always raise eyebrows.
8️⃣ IPO Is 100% Offer for Sale: Company Receives Zero Funds
This point is extremely important for investors.
The Corona Remedies IPO is an entirely Offer for Sale (OFS).
Meaning:
- No money goes to the company
- Only the existing shareholders cash out
- No funds will be used for expansion, R&D, or capacity building
This is the number one reason GMP tends to cool in OFS-heavy IPOs.
What You Should Remember
Investors prefer IPOs where fresh capital strengthens the business—not ones where promoters exit without boosting the company’s balance sheet.
9️⃣ Dependence on 22 C&F Agents
The company depends on a network of 22 Carrying & Forwarding (C&F) agents for distribution.
If even a few of these agents:
- Underperform
- Face operational issues
- Lose interest
- Or terminate contracts
Corona Remedies may face severe supply delays.
What You Should Remember
Distribution is the bloodstream of a pharma company. Any disruption affects nationwide sales almost immediately.
🔟 High Competition From Generics & Biosimilars
Indian pharma is a battlefield.
Competitors:
- Offer cheaper generics
- Have wider networks
- Are backed by global giants
- Move fast on pricing and doctor outreach
Corona Remedies operates in categories where pricing competition is ruthless.
What You Should Remember
Pharma margins vanish quickly when generic players undercut pricing. Only companies with strong branding and differentiation survive long-term.
📌 Why Investor Sentiment Is Mixed
When you combine all these factors…
- High reliance on a few brands
- Geographic concentration
- Heavy dependence on India
- Supply chain risks
- Pricing regulation in chronic therapies
- OFS structure
- Fierce competition
…it becomes clear why the GMP is softening even though brand strength remains intact.
🛏️ Wakefit Innovations IPO: A Very Different Story — Yet Similar Outcome
While Corona Remedies is fighting regulatory and concentration risks, Wakefit Innovations comes from a completely different industry — D2C home solutions.
Yet both IPOs are showing slower-than-expected subscription.
Let’s break down Wakefit’s IPO details first.
Wakefit Innovations IPO: Quick Snapshot
- IPO Size: ₹1,288.89 crore
- Fresh Issue: ₹377.18 crore
- Offer for Sale: ₹911.71 crore
- Price Band: ₹185–₹195
- Lot Size: Minimum 76 shares
- Minimum Investment: ₹14,820
- Opening Date: December 8, 2025
- Closing Date: December 10, 2025
- Listing Date: December 15, 2025
- Registrar: MUFG Intime India
As of Day 1:
- Overall subscription: 0.16×
- Retail: 0.77×
- NII: 0.07×
- QIB: 0.00× (no bids yet)
Grey Market Premium: ₹5
Expected Listing Price: ~₹200
Expected Listing Gain: 2.56%
This means the grey market is predicting a flat to mildly positive listing.
Why Is Wakefit Subscription Slow?
Even though Wakefit is a beloved consumer brand, IPO investors behave differently than shoppers.
Here’s what the market is likely thinking:
1️⃣ Large OFS Portion
Like Corona Remedies, Wakefit also has a sizeable Offer for Sale, which often signals investor exit, not business growth capital.
2️⃣ Mixed profitability track record
D2C brands typically spend heavily on:
- Warehousing
- Last-mile delivery
- Marketing
- Offline store expansion
This sometimes leads to volatile earnings.
3️⃣ Competition in home solutions is rising
India’s furniture + mattress market has big players from:
- Pepperfry
- IKEA
- Urban Ladder
- Sleepyhead
- Duroflex
Wakefit’s differentiation is real — but sustaining margins is a challenge.
4️⃣ IPO pricing may appear tight
A GMP of ₹5 means the market is not pricing in a huge upside yet.
Corona Remedies vs Wakefit: What the Two IPOs Reveal About 2025 Market Mood
Interestingly, both IPOs are showing early signs of investor caution, but for very different reasons.
Corona Remedies:
- Investors are worried about concentration risks
- Pharma regulatory overhangs
- 100% OFS structure
- Rising competition
Wakefit Innovations:
- Mixed profitability typical of D2C brands
- Large OFS
- Low Day 1 QIB participation
- Tight valuations
In short:
Investors in late 2025 are no longer applying blindly to every IPO—selectivity is back.
📘 Conclusion: Should You Invest?
This article is not investment advice, but a contextual breakdown to help you think like an informed investor.
The markets are shifting. Investors are demanding:
- Solid fundamentals
- Clear growth paths
- Fresh capital deployment
- Competitive advantage
- Clean regulatory track records
Both Corona Remedies and Wakefit are strong consumer-facing brands.
But as the DRHP details show, branding doesn’t eliminate risk.
And that’s exactly what the markets seem to be pricing in right now.
What do you think?
Are investors being cautious… or are they missing an opportunity?
Share your thoughts below — your perspective might help another investor.